Press Releases

GlobeNewswire, Inc.

Third Quarter 2026 Revenues of $471.8 Million Reflect 35.7 Percent Growth and 23.2 Percent Organic Growth Over Third Quarter 2025 Revenues of $347.6 Million Kratos Government Solutions Third Quarter 2026 Revenues of $397.2 Million Reflect 35.8...

GlobeNewswire, Inc.

Year Over Year Net Revenue Growth of 18% and Core Programmatic Revenue Growth of 8% for the Three Months Ended September 30, 2026 SOUTH ORANGE, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Nephros, Inc. (Nasdaq: NEPH), a leading water technology...

GlobeNewswire, Inc.

2026 Third Quarter Highlights Net Sales rise 16.7 percent to $2.56 billion Net Sales to Customers Outside the United States increase 28.1 percent to $1.20 billion, representing 47 percent of total Net Sales Net Income Per Diluted Share increases...

GlobeNewswire, Inc.

Delivers revenue growth of 73% in the third quarter and raises full year 2026 revenue guidance AUSTIN, Texas, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI), a medical device company redefining stroke recovery for survivors...

GlobeNewswire, Inc.

Received authorization in the United Kingdom and European Union to expand global first-in-human ASCEND Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP1-related disorder, adding to clearances in Australia and Argentina Company remains...

GlobeNewswire, Inc.

Q3 2026 total revenues of $101.9 million, +24% vs. Q3 2025 Q3 2026 commercial product revenue of $45.0 million, +102% vs. Q3 2025 Furoscix ReadyFlow™ was approved and shipments commenced mid-September Rapid adoption of Furoscix ReadyFlow, making...

GlobeNewswire, Inc.

Q3 2026 revenue of $32.9 million; GAAP basic EPS: $(0.04) Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed SAN DIEGO, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre, Gyre Therapeutics or the Company) (Nasdaq:...

GlobeNewswire, Inc.

Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) completed enrollment with 166 participants randomized; topline results expected mid 2027 Randomized the first participant in its Phase 2a Hybrid CATT1 pilot...

GlobeNewswire, Inc.

Best-in-disease results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 studies showed rapid, profound, sustained efficacy supporting barzolvolimab’s potential to be a transformational therapy in CSU BLA submission for barzolvolimab in CSU anticipated in...

GlobeNewswire, Inc.

Third quarter revenue of $1.1 billion, up 6% year-over-year and up 7% when adjusted for foreign exchange* Cloud Infrastructure Services revenue of $109 million, up 34% year-over-year and up 35% when adjusted for foreign exchange* Security revenue...

GlobeNewswire, Inc.

CAMPBELL, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Arteris, Inc. (Nasdaq: AIP), a leading provider of semiconductor technology for accelerating innovation in the AI era, today announced financial results for the third quarter ended September 30,...

GlobeNewswire, Inc.

Ended the Quarter with a Debt-Free Balance Sheet and $24.5 Million of Cash and Accounts Receivable Reported Total Backlog of $254.5 Million and Opportunity Pipeline of $1.66 billion Expect Record Revenue for Full Year 2026 Conference Call...

GlobeNewswire, Inc.

Enrollment in soquelitinib registrational Phase 3 relapsed/refractory peripheral T-cell lymphoma (PTCL) and Phase 2 atopic dermatitis trials on track Angel Pharmaceuticals completes enrollment in cohort 1 of Phase 1b/2 atopic dermatitis trial;...

GlobeNewswire, Inc.

AMPLIFY-7P Phase 2 pre-specified analyses demonstrate substantial reductions in risk of recurrence or death in ctDNA negative patients and patients without prior radiation, enabling a targeted Phase 3 strategy in adjuvant PDAC; findings presented...

GlobeNewswire, Inc.

REDWOOD CITY, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or the Company), a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism...

GlobeNewswire, Inc.

Advancing a pipeline built entirely on the Alector Brain Carrier (ABC) blood-brain barrier platform, spanning antibody, enzyme, and siRNA programs, with AL137, Alector's lead ABC-enabled anti-amyloid beta (Aβ) antibody program for Alzheimer's...

GlobeNewswire, Inc.

Topline data from 400-person sentinel safety cohort and approximately 5,000 patients in main cohort Phase 2b COVID-19 trial anticipated by mid-year 2027 Expanded intellectual property portfolio with new European patent that further protects core...

GlobeNewswire, Inc.

EMERYVILLE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- NMI Holdings, Inc. (Nasdaq: NMIH) today reported net income of $93.5 million, or $1.23 per diluted share, for the third quarter ended September 30, 2026, compared to $105.8 million, or $1.38...

GlobeNewswire, Inc.

REVTORPYK became commercially available on September 30th for the treatment of patients with HR+/HER2- PIK3CA wild-type locally advanced or metastatic breast cancer 91% of U.S. commercial and Medicare lives are in health plans that cover REVTORPYK...

GlobeNewswire, Inc.

Pivotal Phase 2 ALPHA3 Program in 1L Large B-cell Lymphoma (LBCL): ALPHA3 Enrollment Momentum Continues, Supported by Expanding Trial Network, Increased MRD Screening, and Brisk Enrollment in Asia-Pacific Next ALPHA3 Clinical Update Anticipated in...